CoChat
Sign Up
Cited by 131Chronic Obstructive Pulmonary Disease (COPD) ResearchChemokine receptors and signalingAsthma and respiratory diseases

Chemokines in COPD: From Implication to Therapeutic Use

Open access
Henrot, Pauline, Prevel, Renaud, Berger, Patrick, Dupin, Isabelle·2019·International Journal of Molecular Sciences
DOI 10.3390/ijms20112785PMC PMC6600384
Open this paper in CoChat — free accountOpen PDF

Abstract

Chronic Obstructive Pulmonary Disease (COPD) represents the 3rd leading cause of death in the world. The underlying pathophysiological mechanisms have been the focus of extensive research in the past. The lung has a complex architecture, where structural cells interact continuously with immune cells that infiltrate into the pulmonary tissue. Both types of cells express chemokines and chemokine receptors, making them sensitive to modifications of concentration gradients. Cigarette smoke exposure and recurrent exacerbations, directly and indirectly, impact the expression of chemokines and chemokine receptors. Here, we provide an overview of the evidence regarding chemokines involvement in COPD, and we hypothesize that a dysregulation of this tightly regulated system is critical in COPD evolution, both at a stable state and during exacerbations. Targeting chemokines and chemokine receptors could be highly attractive as a mean to control both chronic inflammation and bronchial remodeling. We present a special focus on the CXCL8-CXCR1/2, CXCL9/10/11-CXCR3, CCL2-CCR2, and CXCL12-CXCR4 axes that seem particularly involved in the disease pathophysiology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20112785

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • COPD is now considered as a systemic inflammatory disease implicating a wide range of cytokines and chemokines and including several comorbidities.

    “COPD should not be limited to its respiratory features and is now considered as a systemic inflammatory disease implicating a wild range of cytokines and chemokines [5] and including several comorbidities.”

    From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [5]

    The Introduction identifies chemokines as cytokines with a pivotal role in COPD, and §3 describes chemokines produced in both the lung and systemic circulation. But §3.3.2 describes a systemic inflammatory response specifically during virus-associated exacerbations; it does not establish the broader characterization of COPD as a systemic inflammatory disease. The comorbidities phrase follows the citation and is not assessed as attributed to this source. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 165

  1. [2]GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016 Lancet Lond. Engl. 2017 390 1211 1259 10.1016/S0140-6736(17)32154-2 PMC5605509 28919117 · DOI · Paper page
  2. [3]Terzikhan N. Verhamme K.M.C. Hofman A. Stricker B.H. Brusselle G.G. Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: The Rotterdam Study Eur. J. Epidemiol. 2016 31 785 792 10.1007/s10654-016-0132-z 26946425 PMC5005388 · DOI
  3. [4]Stoller J.K. Aboussouan L.S. Alpha1-antitrypsin deficiency Lancet Lond. Engl. 2005 365 2225 2236 10.1016/S0140-6736(05)66781-5 15978931 · DOI
  4. [5]Tashkin D.P. Altose M.D. Bleecker E.R. Connett J.E. Kanner R.E. Lee W.W. Wise R. The lung health study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group Am. Rev. Respir. Dis. 1992 145 301 310 10.1164/ajrccm/145.2_Pt_1.301 1736734 · DOI
  5. [6]Stern D.A. Morgan W.J. Wright A.L. Guerra S. Martinez F.D. Poor airway function in early infancy and lung function by age 22 years: A non-selective longitudinal cohort study Lancet Lond. Engl. 2007 370 758 764 10.1016/S0140-6736(07)61379-8 PMC2831283 17765525 · DOI · Paper page
  6. [7]Lange P. Celli B. Agustí A. Boje Jensen G. Divo M. Faner R. Guerra S. Marott J.L. Martinez F.D. Martinez-Camblor P. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease N. Engl. J. Med. 2015 373 111 122 10.1056/NEJMoa1411532 26154786 · DOI · Paper page
  7. [8]Ko F.W. Chan K.P. Hui D.S. Goddard J.R. Shaw J.G. Reid D.W. Yang I.A. Acute exacerbation of COPD Respirol. Carlton VIC 2016 21 1152 1165 10.1111/resp.12780 27028990 PMC7169165 · DOI
  8. [9]Wedzicha J.A. Brill S.E. Allinson J.P. Donaldson G.C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease BMC Med. 2013 11 181 10.1186/1741-7015-11-181 23945277 PMC3750926 · DOI
  9. [10]Calverley P.M.A. Anderson J.A. Celli B. Ferguson G.T. Jenkins C. Jones P.W. Yates J.C. Vestbo J. TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N. Engl. J. Med. 2007 356 775 789 10.1056/NEJMoa063070 17314337 · DOI
  10. [11]Tashkin D.P. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S. Decramer M. UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease N. Engl. J. Med. 2008 359 1543 1554 10.1056/NEJMoa0805800 18836213 · DOI
  11. [12]Vestbo J. Anderson J.A. Brook R.D. Calverley P.M.A. Celli B.R. Crim C. Martinez F. Yates J. Newby D.E. SUMMIT Investigators Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial Lancet Lond. Engl. 2016 387 1817 1826 10.1016/S0140-6736(16)30069-1 27203508 · DOI
  12. [13]Wedzicha J.A. Banerji D. Chapman K.R. Vestbo J. Roche N. Ayers R.T. Thach C. Fogel R. Patalano F. Vogelmeier C.F. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD N. Engl. J. Med. 2016 374 2222 2234 10.1056/NEJMoa1516385 27181606 · DOI
  13. [14]Lipson D.A. Barnhart F. Brealey N. Brooks J. Criner G.J. Day N.C. Dransfield M.T. Halpin D.M.G. Han M.K. Jones C.E. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD N. Engl. J. Med. 2018 378 1671 1680 10.1056/NEJMoa1713901 29668352 · DOI
  14. [15]Barnes P.J. Shapiro S.D. Pauwels R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms Eur. Respir. J. 2003 22 672 688 10.1183/09031936.03.00040703 14582923 · DOI
  15. [16]Dupin I. Contin-Bordes C. Berger P. Fibrocytes in Asthma and Chronic Obstructive Pulmonary Disease: Variations on the Same Theme Am. J. Respir. Cell Mol. Biol. 2018 58 288 298 10.1165/rcmb.2017-0301PS 29087726 · DOI
  16. [17]Baggiolini M. Chemokines and leukocyte traffic Nature 1998 392 565 568 10.1038/33340 9560152 · DOI
  17. [18]Mackay C.R. Chemokines: immunology’s high impact factors Nat. Immunol. 2001 2 95 101 10.1038/84298 11175800 · DOI
  18. [19]Youn B.S. Mantel C. Broxmeyer H.E. Chemokines, chemokine receptors and hematopoiesis Immunol. Rev. 2000 177 150 174 10.1034/j.1600-065X.2000.17701.x 11138773 · DOI
  19. [20]Belperio J.A. Keane M.P. Arenberg D.A. Addison C.L. Ehlert J.E. Burdick M.D. Strieter R.M. CXC chemokines in angiogenesis J. Leukoc. Biol. 2000 68 1 8 10914483
  20. [21]Müller A. Homey B. Soto H. Ge N. Catron D. Buchanan M.E. McClanahan T. Murphy E. Yuan W. Wagner S.N. Involvement of chemokine receptors in breast cancer metastasis Nature 2001 410 50 56 10.1038/35065016 11242036 · DOI · Paper page
  21. [22]Kinter A. Arthos J. Cicala C. Fauci A.S. Chemokines, cytokines and HIV: A complex network of interactions that influence HIV pathogenesis Immunol. Rev. 2000 177 88 98 10.1034/j.1600-065X.2000.17708.x 11138789 · DOI
  22. [23]Koenen R.R. Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis Nat. Rev. Drug Discov. 2010 9 141 153 10.1038/nrd3048 20118962 · DOI
  23. [24]Zlotnik A. Yoshie O. Chemokines: A new classification system and their role in immunity Immunity 2000 12 121 127 10.1016/S1074-7613(00)80165-X 10714678 · DOI
  24. [25]Miller M.C. Mayo K.H. Chemokines from a Structural Perspective Int. J. Mol. Sci. 2017 18 2088 10.3390/ijms18102088 28974038 PMC5666770 · DOI
  25. [26]Allen S.J. Crown S.E. Handel T.M. Chemokine: Receptor structure, interactions, and antagonism Annu. Rev. Immunol. 2007 25 787 820 10.1146/annurev.immunol.24.021605.090529 17291188 · DOI
  26. [27]Nibbs R.J.B. Graham G.J. Immune regulation by atypical chemokine receptors Nat. Rev. Immunol. 2013 13 815 829 10.1038/nri3544 24319779 · DOI
  27. [28]Strieter R.M. Polverini P.J. Kunkel S.L. Arenberg D.A. Burdick M.D. Kasper J. Dzuiba J. Van Damme J. Walz A. Marriott D. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis J. Biol. Chem. 1995 270 27348 27357 10.1074/jbc.270.45.27348 7592998 · DOI · Paper page
  28. [29]Ludeman J.P. Stone M.J. The structural role of receptor tyrosine sulfation in chemokine recognition Br. J. Pharmacol. 2014 171 1167 1179 10.1111/bph.12455 24116930 PMC3952796 · DOI
  29. [30]Veldkamp C.T. Seibert C. Peterson F.C. De la Cruz N.B. Haugner J.C. Basnet H. Sakmar T.P. Volkman B.F. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12 Sci. Signal. 2008 1 ra4 10.1126/scisignal.1160755 18799424 PMC2692298 · DOI
  30. [31]Legler D.F. Thelen M. New insights in chemokine signaling F1000Research 2018 7 95 10.12688/f1000research.13130.1 29416853 PMC5782407 · DOI
  31. [32]Thelen M. Dancing to the tune of chemokines Nat. Immunol. 2001 2 129 134 10.1038/84224 11175805 · DOI
  32. [33]Colamussi M.L. Secchiero P. Gonelli A. Marchisio M. Zauli G. Capitani S. Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway J. Leukoc. Biol. 2001 69 263 270 11272277
  33. [34]Drury L.J. Wendt M.K. Dwinell M.B. CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through Bim-mediated intrinsic apoptosis PLoS ONE 2010 5 e12895 10.1371/journal.pone.0012895 20877573 PMC2943927 · DOI
  34. [35]Kremer K.N. Peterson K.L. Schneider P.A. Meng X.W. Dai H. Hess A.D. Smith B.D. Rodriguez-Ramirez C. Karp J.E. Kaufmann S.H. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak J. Biol. Chem. 2013 288 22899 22914 10.1074/jbc.M113.449926 23798675 PMC3743469 · DOI
  35. [36]Ravi A.K. Plumb J. Gaskell R. Mason S. Broome C.S. Booth G. Catley M. Vestbo J. Singh D. COPD monocytes demonstrate impaired migratory ability Respir. Res. 2017 18 90 10.1186/s12931-017-0569-y 28494757 PMC5425971 · DOI
  36. [37]Kufareva I. Gustavsson M. Zheng Y. Stephens B.S. Handel T.M. What Do Structures Tell Us About Chemokine Receptor Function and Antagonism? Annu. Rev. Biophys. 2017 46 175 198 10.1146/annurev-biophys-051013-022942 28532213 PMC5764094 · DOI
  37. [38]Arimont M. Sun S.-L. Leurs R. Smit M. de Esch I.J.P. de Graaf C. Structural Analysis of Chemokine Receptor-Ligand Interactions J. Med. Chem. 2017 60 4735 4779 10.1021/acs.jmedchem.6b01309 28165741 PMC5483895 · DOI
  38. [39]Proudfoot A.E.I. Uguccioni M. Modulation of Chemokine Responses: Synergy and Cooperativity Front. Immunol. 2016 7 183 10.3389/fimmu.2016.00183 27242790 PMC4871875 · DOI
  39. [40]Schiraldi M. Raucci A. Muñoz L.M. Livoti E. Celona B. Venereau E. Apuzzo T. De Marchis F. Pedotti M. Bachi A. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 J. Exp. Med. 2012 209 551 563 10.1084/jem.20111739 22370717 PMC3302219 · DOI
  40. [41]Campana L. Bosurgi L. Bianchi M.E. Manfredi A.A. Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells J. Leukoc. Biol. 2009 86 609 615 10.1189/jlb.0908576 19414537 · DOI
  41. [42]Proudfoot A.E.I. Chemokines and Glycosaminoglycans Front. Immunol. 2015 6 246 10.3389/fimmu.2015.00246 26074917 PMC4443743 · DOI
  42. [43]Drury L.J. Ziarek J.J. Gravel S. Veldkamp C.T. Takekoshi T. Hwang S.T. Heveker N. Volkman B.F. Dwinell M.B. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways Proc. Natl. Acad. Sci. USA 2011 108 17655 17660 10.1073/pnas.1101133108 21990345 PMC3203819 · DOI
  43. [44]Proudfoot A.E.I. Handel T.M. Johnson Z. Lau E.K. LiWang P. Clark-Lewis I. Borlat F. Wells T.N.C. Kosco-Vilbois M.H. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines Proc. Natl. Acad. Sci. USA 2003 100 1885 1890 10.1073/pnas.0334864100 12571364 PMC149928 · DOI
  44. [45]Burgstaller G. Oehrle B. Gerckens M. White E.S. Schiller H.B. Eickelberg O. The instructive extracellular matrix of the lung: Basic composition and alterations in chronic lung disease Eur. Respir. J. 2017 50 1601805 10.1183/13993003.01805-2016 28679607 · DOI
  45. [46]Sand J.M.B. Knox A.J. Lange P. Sun S. Kristensen J.H. Leeming D.J. Karsdal M.A. Bolton C.E. Johnson S.R. Accelerated extracellular matrix turnover during exacerbations of COPD Respir. Res. 2015 16 69 10.1186/s12931-015-0225-3 26062683 PMC4491243 · DOI
  46. [47]Mestas J. Hughes C.C.W. Of Mice and Not Men: Differences between Mouse and Human Immunology J. Immunol. 2004 172 2731 2738 10.4049/jimmunol.172.5.2731 14978070 · DOI · Paper page
  47. [48]Du Y. Deng W. Wang Z. Ning M. Zhang W. Zhou Y. Lo E.H. Xing C. Differential subnetwork of chemokines/cytokines in human, mouse, and rat brain cells after oxygen-glucose deprivation J. Cereb. Blood Flow Metab. 2017 37 1425 1434 10.1177/0271678X16656199 27328691 PMC5453462 · DOI
  48. [49]Weber M. Hauschild R. Schwarz J. Moussion C. de Vries I. Legler D.F. Luther S.A. Bollenbach T. Sixt M. Interstitial dendritic cell guidance by haptotactic chemokine gradients Science 2013 339 328 332 10.1126/science.1228456 23329049 · DOI · Paper page
  49. [50]Phillips R.J. Burdick M.D. Hong K. Lutz M.A. Murray L.A. Xue Y.Y. Belperio J.A. Keane M.P. Strieter R.M. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis J. Clin. Investig. 2004 114 438 446 10.1172/JCI200420997 15286810 PMC484979 · DOI
  50. [51]Gangavarapu P. Rajagopalan L. Kolli D. Guerrero-Plata A. Garofalo R.P. Rajarathnam K. The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissue-specific neutrophil recruitment J. Leukoc. Biol. 2012 91 259 265 10.1189/jlb.0511239 22140266 PMC3290428 · DOI
  51. [52]Tanino Y. Coombe D.R. Gill S.E. Kett W.C. Kajikawa O. Proudfoot A.E.I. Wells T.N.C. Parks W.C. Wight T.N. Martin T.R. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs J. Immunol. 2010 184 2677 2685 10.4049/jimmunol.0903274 20124102 PMC4113427 · DOI
  52. [54]Pauwels R.A. Buist A.S. Calverley P.M. Jenkins C.R. Hurd S.S. GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Am. J. Respir. Crit. Care Med. 2001 163 1256 1276 10.1164/ajrccm.163.5.2101039 11316667 · DOI
  53. [55]Inui T. Watanabe M. Nakamoto K. Sada M. Hirata A. Nakamura M. Honda K. Ogawa Y. Takata S. Yokoyama T. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: A potential role in the pathogenesis of COPD Exp. Lung Res. 2019 44 323 331 10.1080/01902148.2018.1520936 30676127 · DOI
  54. [56]Traves S.L. Culpitt S.V. Russell R.E.K. Barnes P.J. Donnelly L.E. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD Thorax 2002 57 590 595 10.1136/thorax.57.7.590 12096201 PMC1746378 · DOI
  55. [57]Beeh K.M. Kornmann O. Buhl R. Culpitt S.V. Giembycz M.A. Barnes P.J. Neutrophil chemotactic activity of sputum from patients with COPD: Role of interleukin 8 and leukotriene B4 Chest 2003 123 1240 1247 10.1378/chest.123.4.1240 12684317 · DOI
  56. [58]Qiu Y. Zhu J. Bandi V. Atmar R.L. Hattotuwa K. Guntupalli K.K. Jeffery P.K. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2003 168 968 975 10.1164/rccm.200208-794OC 12857718 · DOI
  57. [59]Stefano A.D. Caramori G. Gnemmi I. Contoli M. Bristot L. Capelli A. Ricciardolo F.L.M. Magno F. D’Anna S.E. Zanini A. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD Thorax 2009 64 968 975 10.1136/thx.2009.113647 19703829 · DOI
  58. [60]Keatings V.M. Collins P.D. Scott D.M. Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma Am. J. Respir. Crit. Care Med. 1996 153 530 534 10.1164/ajrccm.153.2.8564092 8564092 · DOI
  59. [61]Osei E.T. Noordhoek J.A. Hackett T.L. Spanjer A.I.R. Postma D.S. Timens W. Brandsma C.-A. Heijink I.H. Interleukin-1α drives the dysfunctional cross-talk of the airway epithelium and lung fibroblasts in COPD Eur. Respir. J. 2016 48 359 369 10.1183/13993003.01911-2015 27418555 · DOI
  60. [62]Patel B.S. Kugel M.J. Baehring G. Ammit A.J. Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect Pulm. Pharmacol. Ther. 2017 45 34 39 10.1016/j.pupt.2017.04.006 28414142 · DOI
  61. [63]Ikari J. Nelson A.J. Obaid J. Giron-Martinez A. Ikari K. Makino F. Iwasawa S. Gunji Y. Farid M. Wang X. Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease PLoS ONE 2017 12 e0184039 10.1371/journal.pone.0184039 28880936 PMC5589164 · DOI
  62. [64]De Llano L.P. Cosío B.G. Iglesias A. de Las Cuevas N. Soler-Cataluña J.J. Izquierdo J.L. López-Campos J.L. Calero C. Plaza V. Miravitlles M. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: A network approach Int. J. Chronic Obstruct. Pulm. Dis. 2018 13 591 601 10.2147/COPD.S153694 29483774 PMC5813946 · DOI
  63. [65]De Boer W.I. Sont J.K. van Schadewijk A. Stolk J. van Krieken J.H. Hiemstra P.S. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD J. Pathol. 2000 190 619 626 10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6 10727989 · DOI
  64. [66]Belchamber K.B.R. Donnelly L.E. Macrophage Dysfunction in Respiratory Disease Results Probl. Cell Differ. 2017 62 299 313 28455714
  65. [67]Huang Z.-W. Lien G.-S. Lin C.-H. Jiang C.-P. Chen B.-C. p300 and C/EBPβ-regulated IKKβ expression are involved in thrombin-induced IL-8/CXCL8 expression in human lung epithelial cells Pharmacol. Res. 2017 121 33 41 10.1016/j.phrs.2017.04.020 28428115 · DOI
  66. [68]Costa C. Rufino R. Traves S.L. Lapa E Silva J.R. Barnes P.J. Donnelly L.E. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD Chest 2008 133 26 33 10.1378/chest.07-0393 17925429 · DOI
  67. [69]Kelsen S.G. Aksoy M.O. Georgy M. Hershman R. Ji R. Li X. Hurford M. Solomides C. Chatila W. Kim V. Lymphoid Follicle Cells in Chronic Obstructive Pulmonary Disease Overexpress the Chemokine Receptor CXCR3 Am. J. Respir. Crit. Care Med. 2009 179 799 805 10.1164/rccm.200807-1089OC 19218194 PMC5803653 · DOI
  68. [70]Tura-Ceide O. Lobo B. Paul T. Puig-Pey R. Coll-Bonfill N. García-Lucio J. Smolders V. Blanco I. Barberà J.A. Peinado V.I. Cigarette smoke challenges bone marrow mesenchymal stem cell capacities in guinea pig Respir. Res. 2017 18 50 10.1186/s12931-017-0530-0 28330488 PMC5363047 · DOI
  69. [71]Hardaker E.L. Bacon A.M. Carlson K. Roshak A.K. Foley J.J. Schmidt D.B. Buckley P.T. Comegys M. Panettieri R.A. Sarau H.M. Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: Participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004 18 191 193 14597565
  70. [72]Saetta M. Mariani M. Panina-Bordignon P. Turato G. Buonsanti C. Baraldo S. Bellettato C.M. Papi A. Corbetta L. Zuin R. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2002 165 1404 1409 10.1164/rccm.2107139 12016104 · DOI
  71. [73]Quint J.K. Donaldson G.C. Goldring J.J.P. Baghai-Ravary R. Hurst J.R. Wedzicha J.A. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD Chest 2010 137 812 822 10.1378/chest.09-1541 19837822 PMC2851557 · DOI
  72. [74]Barwinska D. Oueini H. Poirier C. Albrecht M.E. Bogatcheva N.V. Justice M.J. Saliba J. Schweitzer K.S. Broxmeyer H.E. March K.L. AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice Am. J. Physiol. Lung Cell. Mol. Physiol. 2018 315 L382 L386 10.1152/ajplung.00185.2018 29745251 PMC6172621 · DOI
  73. [75]Karagiannis K. Proklou A. Tsitoura E. Lasithiotaki I. Kalpadaki C. Moraitaki D. Sperelakis I. Kontakis G. Antoniou K.M. Tzanakis N. Impaired mRNA Expression of the Migration Related Chemokine Receptor CXCR4 in Mesenchymal Stem Cells of COPD Patients Int. J. Inflamm. 2017 2017 6089425 10.1155/2017/6089425 PMC5539942 28804668 · DOI
  74. [76]Dupin I. Allard B. Ozier A. Maurat E. Ousova O. Delbrel E. Trian T. Bui H.-N. Dromer C. Guisset O. Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway J. Allergy Clin. Immunol. 2016 137 1036.e7 1042.e7 10.1016/j.jaci.2015.08.043 26602164 · DOI
  75. [77]Vishweswaraiah S. Thimraj T.A. George L. Krishnarao C.S. Lokesh K.S. Siddaiah J.B. Larsson K. Upadhyay S. Palmberg L. Anand M.P. Putative Systemic Biomarkers of Biomass Smoke-Induced Chronic Obstructive Pulmonary Disease among Women in a Rural South Indian Population Dis. Mark. 2018 2018 4949175 10.1155/2018/4949175 30595762 PMC6282129 · DOI
  76. [78]Marques P. Collado A. Escudero P. Rius C. González C. Servera E. Piqueras L. Sanz M.-J. Cigarette Smoke Increases Endothelial CXCL16-Leukocyte CXCR6 Adhesion In Vitro and In Vivo. Potential Consequences in Chronic Obstructive Pulmonary Disease Front. Immunol. 2017 8 1766 10.3389/fimmu.2017.01766 29326688 PMC5733535 · DOI
  77. [79]Jing H. Liu L. Zhou J. Yao H. Inhibition of C-X-C Motif Chemokine 10 (CXCL10) Protects Mice from Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2018 24 5748 5753 10.12659/MSM.909864 PMC6109363 30118441 · DOI
  78. [80]Di Stefano A. Coccini T. Roda E. Signorini C. Balbi B. Brunetti G. Ceriana P. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema Int. J. Chronic Obstruct. Pulm. Dis. 2018 13 1691 1700 10.2147/COPD.S159915 PMC5973466 29872287 · DOI
  79. [81]Ravi A.K. Khurana S. Lemon J. Plumb J. Booth G. Healy L. Catley M. Vestbo J. Singh D. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum Respir. Res. 2014 15 103 10.1186/s12931-014-0103-4 25183374 PMC4156958 · DOI
  80. [82]Bradford E. Jacobson S. Varasteh J. Comellas A.P. Woodruff P. O’Neal W. DeMeo D.L. Li X. Kim V. Cho M. The value of blood cytokines and chemokines in assessing COPD Respir. Res. 2017 18 180 10.1186/s12931-017-0662-2 29065892 PMC5655820 · DOI
  81. [83]D’Armiento J.M. Scharf S.M. Roth M.D. Connett J.E. Ghio A. Sternberg D. Goldin J.G. Louis T.A. Mao J.T. O’Connor G.T. Eosinophil and T cell markers predict functional decline in COPD patients Respir. Res. 2009 10 113 10.1186/1465-9921-10-113 19925666 PMC2785783 · DOI
  82. [84]Bocchino V. Bertorelli G. Bertrand C.P. Ponath P.D. Newman W. Franco C. Marruchella A. Merlini S. Del Donno M. Zhuo X. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis Allergy 2002 57 17 22 11991282
  83. [85]Miller M. Ramsdell J. Friedman P.J. Cho J.Y. Renvall M. Broide D.H. Computed tomographic scan-diagnosed chronic obstructive pulmonary disease-emphysema: Eotaxin-1 is associated with bronchodilator response and extent of emphysema J. Allergy Clin. Immunol. 2007 120 1118 1125 10.1016/j.jaci.2007.08.045 17983873 · DOI
  84. [86]Sin D.D. Miller B.E. Duvoix A. Man S.F.P. Zhang X. Silverman E.K. Connett J.E. Anthonisen N.A. Wise R.A. Tashkin D. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2011 183 1187 1192 10.1164/rccm.201008-1220OC 21216880 PMC3114051 · DOI
  85. [87]Muñoz-Esquerre M. Aliagas E. López-Sánchez M. Escobar I. Huertas D. Penín R. Dorca J. Santos S. Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine) PLoS ONE 2017 12 e0177218 10.1371/journal.pone.0177218 28545096 PMC5436690 · DOI
  86. [88]Demedts I.K. Bracke K.R. Van Pottelberge G. Testelmans D. Verleden G.M. Vermassen F.E. Joos G.F. Brusselle G.G. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2007 175 998 1005 10.1164/rccm.200608-1113OC 17332482 · DOI
  87. [89]Hao W. Li M. Zhang C. Zhang Y. Xue Y. High Serum Fractalkine/CX3CL1 in Patients with Chronic Obstructive Pulmonary Disease: Relationship with Emphysema Severity and Frequent Exacerbation Lung 2019 197 29 35 10.1007/s00408-018-0176-9 30382361 · DOI
  88. [90]Barnes P.J. The Cytokine Network in Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol. 2009 41 631 638 10.1165/rcmb.2009-0220TR 19717810 · DOI
  89. [91]Kim V. Cornwell W.D. Oros M. Durra H. Criner G.J. Rogers T.J. Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease BMC Pulm. Med. 2015 15 111 10.1186/s12890-015-0103-2 26424214 PMC4589974 · DOI
  90. [92]Ying S. O’Connor B. Ratoff J. Meng Q. Fang C. Cousins D. Zhang G. Gu S. Gao Z. Shamji B. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease J. Immunol. 2008 181 2790 2798 10.4049/jimmunol.181.4.2790 18684970 · DOI
  91. [93]Tanino M. Betsuyaku T. Takeyabu K. Tanino Y. Yamaguchi E. Miyamoto K. Nishimura M. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema Thorax 2002 57 405 411 10.1136/thorax.57.5.405 11978916 PMC1746319 · DOI
  92. [94]Yamamoto C. Yoneda T. Yoshikawa M. Fu A. Tokuyama T. Tsukaguchi K. Narita N. Airway inflammation in COPD assessed by sputum levels of interleukin-8 Chest 1997 112 505 510 10.1378/chest.112.2.505 9266891 · DOI
  93. [95]Woolhouse I.S. Bayley D.L. Stockley R.A. Sputum chemotactic activity in chronic obstructive pulmonary disease: Effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8 Thorax 2002 57 709 714 10.1136/thorax.57.8.709 12149532 PMC1746407 · DOI
  94. [96]Peveri P. Walz A. Dewald B. Baggiolini M. A novel neutrophil-activating factor produced by human mononuclear phagocytes J. Exp. Med. 1988 167 1547 1559 10.1084/jem.167.5.1547 2835419 PMC2188939 · DOI
  95. [97]Zarcone M.C. Duistermaat E. Alblas M.J. van Schadewijk A. Ninaber D.K. Clarijs V. Moerman M.M. Vaessen D. Hiemstra P.S. Kooter I.M. Effect of diesel exhaust generated by a city bus engine on stress responses and innate immunity in primary bronchial epithelial cell cultures Toxicol. In Vitro Int. J. Publ. Assoc. BIBRA 2018 48 221 231 10.1016/j.tiv.2018.01.024 29408669 · DOI
  96. [98]Liu L. Wan C. Zhang W. Guan L. Tian G. Zhang F. Ding W. MiR-146a regulates PM1-induced inflammation via NF-κB signaling pathway in BEAS-2B cells Environ. Toxicol. 2018 33 743 751 10.1002/tox.22561 29667303 · DOI
  97. [99]Sangiorgi C. Vallese D. Gnemmi I. Bucchieri F. Balbi B. Brun P. Leone A. Giordano A. Conway de Macario E. Macario A.J. HSP60 activity on human bronchial epithelial cells Int. J. Immunopathol. Pharmacol. 2017 30 333 340 10.1177/0394632017734479 28976240 PMC5806805 · DOI
  98. [100]Reutershan J. Morris M.A. Burcin T.L. Smith D.F. Chang D. Saprito M.S. Ley K. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung J. Clin. Investig. 2006 116 695 702 10.1172/JCI27009 16485040 PMC1366502 · DOI
  99. [101]Jiang J.-X. Zhang S.-J. Shen H.-J. Guan Y. Liu Q. Zhao W. Jia Y.-L. Shen J. Yan X.-F. Xie Q.-M. Rac1 signaling regulates cigarette smoke-induced inflammation in the lung via the Erk1/2 MAPK and STAT3 pathways Biochim. Biophys. Acta Mol. Basis Dis. 2017 1863 1778 1788 10.1016/j.bbadis.2017.04.013 28428003 · DOI
  100. [102]Aaron S.D. Angel J.B. Lunau M. Wright K. Fex C. Le Saux N. Dales R.E. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2001 163 349 355 10.1164/ajrccm.163.2.2003122 11179105 · DOI
  101. [103]Mikami M. Llewellyn-Jones C.G. Bayley D. Hill S.L. Stockley R.A. The chemotactic activity of sputum from patients with bronchiectasis Am. J. Respir. Crit. Care Med. 1998 157 723 728 10.1164/ajrccm.157.3.9606120 9517582 · DOI
  102. [104]Zhang J. Bai C. The Significance of Serum Interleukin-8 in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Tanaffos 2018 17 13 21 30116274 PMC6087525
  103. [105]Han M.K. Quibrera P.M. Carretta E.E. Barr R.G. Bleecker E.R. Bowler R.P. Cooper C.B. Comellas A. Couper D.J. Curtis J.L. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: An analysis of the SPIROMICS cohort Lancet Respir. Med. 2017 5 619 626 10.1016/S2213-2600(17)30207-2 28668356 PMC5558856 · DOI
  104. [106]Soler N. Ewig S. Torres A. Filella X. Gonzalez J. Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease Eur. Respir. J. 1999 14 1015 1022 10.1183/09031936.99.14510159 10596683 · DOI
  105. [107]Nakajima M. Kawaguchi M. Matsuyama M. Ota K. Fujita J. Matsukura S. Huang S.-K. Morishima Y. Ishii Y. Satoh H. Transcription Elongation Factor P-TEFb Is Involved in IL-17F Signaling in Airway Smooth Muscle Cells Int. Arch. Allergy Immunol. 2018 176 83 90 10.1159/000488154 29649811 · DOI
  106. [108]Donnelly L.E. Barnes P.J. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease Trends Pharmacol. Sci. 2006 27 546 553 10.1016/j.tips.2006.08.001 16911834 · DOI
  107. [109]Pechkovsky D.V. Goldmann T. Ludwig C. Prasse A. Vollmer E. Müller-Quernheim J. Zissel G. CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II Respir. Res. 2005 6 75 10.1186/1465-9921-6-75 16033640 PMC1185567 · DOI
  108. [110]Sauty A. Dziejman M. Taha R.A. Iarossi A.S. Neote K. Garcia-Zepeda E.A. Hamid Q. Luster A.D. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells J. Immunol. 1999 162 3549 3558 10092813
  109. [111]Groom J.R. Luster A.D. CXCR3 ligands: Redundant, collaborative and antagonistic functions Immunol. Cell Biol. 2011 89 207 215 10.1038/icb.2010.158 21221121 PMC3863330 · DOI
  110. [112]Barnes P.J. Cellular and molecular mechanisms of asthma and COPD Clin. Sci. Lond. Engl. 2017 131 1541 1558 10.1042/CS20160487 28659395 · DOI
  111. [113]Costa C. Traves S.L. Tudhope S.J. Fenwick P.S. Belchamber K.B.R. Russell R.E.K. Barnes P.J. Donnelly L.E. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD Eur. Respir. J. 2016 47 1093 1102 10.1183/13993003.01642-2015 26965295 · DOI
  112. [114]Cole K.E. Strick C.A. Paradis T.J. Ogborne K.T. Loetscher M. Gladue R.P. Lin W. Boyd J.G. Moser B. Wood D.E. Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3 J. Exp. Med. 1998 187 2009 2021 10.1084/jem.187.12.2009 9625760 PMC2212354 · DOI · Paper page
  113. [116]Cosio M.G. Majo J. Cosio M.G. Inflammation of the airways and lung parenchyma in COPD: Role of T cells Chest 2002 121 160S 165S 10.1378/chest.121.5_suppl.160S 12010846 · DOI
  114. [117]Porter J.C. Falzon M. Hall A. Polarized localization of epithelial CXCL11 in chronic obstructive pulmonary disease and mechanisms of T cell egression J. Immunol. 2008 180 1866 1877 10.4049/jimmunol.180.3.1866 18209084 PMC2274894 · DOI
  115. [118]Warwick G. Thomas P.S. Yates D.H. Non-invasive biomarkers in exacerbations of obstructive lung disease Respirol. Carlton VIC 2013 18 874 884 10.1111/resp.12089 23521049 · DOI
  116. [119]Bafadhel M. McKenna S. Terry S. Mistry V. Reid C. Haldar P. McCormick M. Haldar K. Kebadze T. Duvoix A. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers Am. J. Respir. Crit. Care Med. 2011 184 662 671 10.1164/rccm.201104-0597OC 21680942 · DOI
  117. [120]Clarke D.L. Clifford R.L. Jindarat S. Proud D. Pang L. Belvisi M. Knox A.J. TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein J. Biol. Chem. 2010 285 29101 29110 10.1074/jbc.M109.099952 20833730 PMC2937941 · DOI
  118. [121]Cole A.M. Ganz T. Liese A.M. Burdick M.D. Liu L. Strieter R.M. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity J. Immunol. 2001 167 623 627 10.4049/jimmunol.167.2.623 11441062 · DOI
  119. [122]Bai J. Song H. Cai C. Zhang M. Xu S. Tan J. The association of monocyte chemotactic protein-1 and CC chemokine receptor 2 gene variants with chronic obstructive pulmonary disease DNA Cell Biol. 2012 31 1058 1063 10.1089/dna.2011.1520 22276574 · DOI
  120. [123]Zheng J. Shi Y. Xiong L. Zhang W. Li Y. Gibson P.G. Simpson J.L. Zhang C. Lu J. Sai J. The Expression of IL-6, TNF-α, and MCP-1 in Respiratory Viral Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease J. Immunol. Res. 2017 2017 8539294 10.1155/2017/8539294 28352642 PMC5352889 · DOI
  121. [124]Ishii T. Hosoki K. Nikura Y. Yamashita N. Nagase T. Yamashita N. IFN Regulatory Factor 3 Potentiates Emphysematous Aggravation by Lipopolysaccharide J. Immunol. 2017 198 3637 3649 10.4049/jimmunol.1601069 28363903 · DOI
  122. [125]Ding L. Morrison S.J. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches Nature 2013 495 231 235 10.1038/nature11885 23434755 PMC3600153 · DOI
  123. [126]Gomperts B.N. Belperio J.A. Rao P.N. Randell S.H. Fishbein M.C. Burdick M.D. Strieter R.M. Circulating progenitor epithelial cells traffic via CXCR4/CXCL12 in response to airway injury J. Immunol. 2006 176 1916 1927 10.4049/jimmunol.176.3.1916 16424223 · DOI
  124. [127]Hattori K. Heissig B. Tashiro K. Honjo T. Tateno M. Shieh J.H. Hackett N.R. Quitoriano M.S. Crystal R.G. Rafii S. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells Blood 2001 97 3354 3360 10.1182/blood.V97.11.3354 11369624 · DOI
  125. [128]Salcedo R. Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses Microcirculation 2003 10 359 370 10.1080/mic.10.3-4.359.370 12851652 · DOI
  126. [129]Balabanian K. Lagane B. Infantino S. Chow K.Y.C. Harriague J. Moepps B. Arenzana-Seisdedos F. Thelen M. Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes J. Biol. Chem. 2005 280 35760 35766 10.1074/jbc.M508234200 16107333 · DOI
  127. [130]Dupin I. Thumerel M. Maurat E. Coste F. Eyraud E. Begueret H. Trian T. Montaudon M. Marthan R. Girodet P.-O. Fibrocyte accumulation in the airway walls of COPD patients Eur. Respir. J. in press 31196946
  128. [131]Liu X. Xie C. Human endothelial progenitor cells isolated from COPD patients are dysfunctional Mol. Cell. Biochem. 2012 363 53 63 10.1007/s11010-011-1157-y 22139347 · DOI
  129. [132]Lim K. Hyun Y.-M. Lambert-Emo K. Capece T. Bae S. Miller R. Topham D.J. Kim M. Neutrophil trails guide influenza-specific CD8+ T cells in the airways Science 2015 349 aaa4352 10.1126/science.aaa4352 26339033 PMC4809646 · DOI
  130. [133]Dahl M. Tybjaerg-Hansen A. Vestbo J. Lange P. Nordestgaard B.G. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2001 164 1008 1011 10.1164/ajrccm.164.6.2010067 11587987 · DOI
  131. [134]Dahl M. Vestbo J. Lange P. Bojesen S.E. Tybjaerg-Hansen A. Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2007 175 250 255 10.1164/rccm.200605-713OC 17053205 · DOI
  132. [135]Cheng D.T. Kim D.K. Cockayne D.A. Belousov A. Bitter H. Cho M.H. Duvoix A. Edwards L.D. Lomas D.A. Miller B.E. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2013 188 948 957 10.1164/rccm.201302-0247OC 23947473 · DOI
  133. [136]Winkler C. Atochina-Vasserman E.N. Holz O. Beers M.F. Erpenbeck V.J. Krug N. Roepcke S. Lauer G. Elmlinger M. Hohlfeld J.M. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD Respir. Res. 2011 12 29 10.1186/1465-9921-12-29 21396106 PMC3061904 · DOI
  134. [137]Coxson H.O. Dirksen A. Edwards L.D. Yates J.C. Agusti A. Bakke P. Calverley P.M. Celli B. Crim C. Duvoix A. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: A prospective analysis from the ECLIPSE study Lancet Respir. Med. 2013 1 129 136 10.1016/S2213-2600(13)70006-7 24429093 · DOI
  135. [138]Lomas D.A. Silverman E.K. Edwards L.D. Miller B.E. Coxson H.O. Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort Thorax 2008 63 1058 1063 10.1136/thx.2008.102574 18757456 · DOI
  136. [139]Faner R. Tal-Singer R. Riley J.H. Celli B. Vestbo J. MacNee W. Bakke P. Calverley P.M.A. Coxson H. Crim C. Lessons from ECLIPSE: A review of COPD biomarkers Thorax 2014 69 666 672 10.1136/thoraxjnl-2013-204778 24310110 · DOI
  137. [140]Baker J.R. Vuppusetty C. Colley T. Hassibi S. Fenwick P.S. Donnelly L.E. Ito K. Barnes P.J. MicroRNA-570 is a novel regulator of cellular senescence and inflammaging FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2018 33 1605 1616 10.1096/fj.201800965R PMC6338629 30156909 · DOI
  138. [141]De Novaes Rocha N. de Oliveira M.V. Braga C.L. Guimarães G. de Albuquerque Maia L. de Araújo Padilha G. Silva J.D. Takiya C.M. Capelozzi V.L. Silva P.L. Ghrelin therapy improves lung and cardiovascular function in experimental emphysema Respir. Res. 2017 18 185 10.1186/s12931-017-0668-9 29100513 PMC5670513 · DOI
  139. [142]Wang Y. Zhou Q. Dong L. Xiong M. Jiang H. Guo M. Zhao L. Yuan L. Li Z. Liu H. The effects of CXCL10 polymorphisms on COPD susceptibility Mol. Genet. Genom. MGG 2018 293 649 655 10.1007/s00438-017-1408-z 29285564 · DOI
  140. [143]Devine S.M. Flomenberg N. Vesole D.H. Liesveld J. Weisdorf D. Badel K. Calandra G. DiPersio J.F. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2004 22 1095 1102 10.1200/JCO.2004.07.131 15020611 · DOI
  141. [144]Gulick R.M. Lalezari J. Goodrich J. Clumeck N. DeJesus E. Horban A. Nadler J. Clotet B. Karlsson A. Wohlfeiler M. Maraviroc for previously treated patients with R5 HIV-1 infection N. Engl. J. Med. 2008 359 1429 1441 10.1056/NEJMoa0803152 18832244 PMC3078519 · DOI
  142. [145]Hitchinson B. Eby J.M. Gao X. Guite-Vinet F. Ziarek J.J. Abdelkarim H. Lee Y. Okamoto Y. Shikano S. Majetschak M. Biased antagonism of CXCR4 avoids antagonist tolerance Sci. Signal. 2018 11 eaat2214 10.1126/scisignal.aat2214 30327409 PMC6422681 · DOI
  143. [146]Galzi J.-L. Hachet-Haas M. Bonnet D. Daubeuf F. Lecat S. Hibert M. Haiech J. Frossard N. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications Pharmacol. Ther. 2010 126 39 55 10.1016/j.pharmthera.2009.12.003 20117133 PMC7112609 · DOI
  144. [147]Von Hundelshausen P. Agten S.M. Eckardt V. Blanchet X. Schmitt M.M. Ippel H. Neideck C. Bidzhekov K. Leberzammer J. Wichapong K. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation Sci. Transl. Med. 2017 9 eaah6650 10.1126/scitranslmed.aah6650 28381538 · DOI
  145. [148]Mahler D.A. Huang S. Tabrizi M. Bell G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study Chest 2004 126 926 934 10.1378/chest.126.3.926 15364775 · DOI
  146. [149]Dyer D.P. Thomson J.M. Hermant A. Jowitt T.A. Handel T.M. Proudfoot A.E.I. Day A.J. Milner C.M. TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8 J. Immunol. 2014 192 2177 2185 10.4049/jimmunol.1300194 24501198 PMC3988464 · DOI
  147. [150]Stevenson C.S. Coote K. Webster R. Johnston H. Atherton H.C. Nicholls A. Giddings J. Sugar R. Jackson A. Press N.J. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect Am. J. Physiol. Lung Cell. Mol. Physiol. 2005 288 L514 L522 10.1152/ajplung.00317.2004 15516486 · DOI
  148. [151]Thatcher T.H. McHugh N.A. Egan R.W. Chapman R.W. Hey J.A. Turner C.K. Redonnet M.R. Seweryniak K.E. Sime P.J. Phipps R.P. Role of CXCR2 in cigarette smoke-induced lung inflammation Am. J. Physiol. Lung Cell. Mol. Physiol. 2005 289 L322 L328 10.1152/ajplung.00039.2005 15833762 PMC2491909 · DOI
  149. [152]Rennard S.I. Dale D.C. Donohue J.F. Kanniess F. Magnussen H. Sutherland E.R. Watz H. Lu S. Stryszak P. Rosenberg E. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med. 2015 191 1001 1011 10.1164/rccm.201405-0992OC 25695403 · DOI
  150. [153]Lazaar A.L. Miller B.E. Tabberer M. Yonchuk J. Leidy N. Ambery C. Bloomer J. Watz H. Tal-Singer R. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD Eur. Respir. J. 2018 52 1801020 10.1183/13993003.01020-2018 30139779 · DOI
  151. [154]Planagumà A. Domènech T. Pont M. Calama E. García-González V. López R. Aulí M. López M. Fonquerna S. Ramos I. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation Pulm. Pharmacol. Ther. 2015 34 37 45 10.1016/j.pupt.2015.08.002 26271598 · DOI
  152. [155]Leaker B.R. Barnes P.J. O’Connor B. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist Respir. Res. 2013 14 137 10.1186/1465-9921-14-137 24341382 PMC3867427 · DOI
  153. [156]Andrews S.P. Cox R.J. Small Molecule CXCR3 Antagonists J. Med. Chem. 2016 59 2894 2917 10.1021/acs.jmedchem.5b01337 26535614 · DOI
  154. [157]Takekoshi T. Ziarek J.J. Volkman B.F. Hwang S.T. A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability Mol. Cancer Ther. 2012 11 2516 2525 10.1158/1535-7163.MCT-12-0494 22869557 PMC3496366 · DOI
  155. [158]Smith E.W. Liu Y. Getschman A.E. Peterson F.C. Ziarek J.J. Li R. Volkman B.F. Chen Y. Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine J. Med. Chem. 2014 57 9693 9699 10.1021/jm501194p 25356720 PMC4255719 · DOI
  156. [159]Veldkamp C.T. Ziarek J.J. Peterson F.C. Chen Y. Volkman B.F. Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design J. Am. Chem. Soc. 2010 132 7242 7243 10.1021/ja1002263 20459090 PMC2941798 · DOI
  157. [160]Hachet-Haas M. Balabanian K. Rohmer F. Pons F. Franchet C. Lecat S. Chow K.Y.C. Dagher R. Gizzi P. Didier B. Small neutralizing molecules to inhibit actions of the chemokine CXCL12 J. Biol. Chem. 2008 283 23189 23199 10.1074/jbc.M803947200 18556651 · DOI
  158. [161]Hoellenriegel J. Zboralski D. Maasch C. Rosin N.Y. Wierda W.G. Keating M.J. Kruschinski A. Burger J.A. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization Blood 2014 123 1032 1039 10.1182/blood-2013-03-493924 24277076 PMC4123413 · DOI
  159. [162]Peng D. Cao B. Zhou Y.-J. Long Y.-Q. The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential Eur. J. Med. Chem. 2018 149 148 169 10.1016/j.ejmech.2018.02.043 29500940 · DOI
  160. [163]McDermott D.H. Pastrana D.V. Calvo K.R. Pittaluga S. Velez D. Cho E. Liu Q. Trout H.H. Neves J.F. Gardner P.J. Plerixafor for the Treatment of WHIM Syndrome N. Engl. J. Med. 2019 380 163 170 10.1056/NEJMoa1808575 30625055 PMC6425947 · DOI
  161. [164]Bonig H. Chudziak D. Priestley G. Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100 Exp. Hematol. 2009 37 402 415.e1 10.1016/j.exphem.2008.10.017 19157683 PMC2669109 · DOI
  162. [165]Cardones A.R. Murakami T. Hwang S.T. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin Cancer Res. 2003 63 6751 6757 14583470
  163. [166]Devi S. Wang Y. Chew W.K. Lima R. A-González N. Mattar C.N.Z. Chong S.Z. Schlitzer A. Bakocevic N. Chew S. Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow J. Exp. Med. 2013 210 2321 2336 10.1084/jem.20130056 24081949 PMC3804935 · DOI
  164. [167]Jujo K. Hamada H. Iwakura A. Thorne T. Sekiguchi H. Clarke T. Ito A. Misener S. Tanaka T. Klyachko E. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction Proc. Natl. Acad. Sci. USA 2010 107 11008 11013 10.1073/pnas.0914248107 20534467 PMC2890743 · DOI
  165. [168]Luo Y. Zhao X. Zhou X. Ji W. Zhang L. Luo T. Liu H. Huang T. Jiang T. Li Y. Short-term intermittent administration of CXCR4 antagonist AMD3100 facilitates myocardial repair in experimental myocardial infarction Acta Biochim. Biophys. Sin. 2013 45 561 569 10.1093/abbs/gmt045 23676772 · DOI

Cited by

Sorted by citations

Authors
Henrot, P., Prevel, R., Berger, P., & Dupin, I.
Affiliations
  • Inserm (FR)
  • Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC 1401, F-33604 Pessac, France
Corresponding author
Dupin, Isabelle
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-06-06
Volume
20
Issue
11
Pages
2785
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms20112785
PMC
PMC6600384
OpenAlex
W2948755509
Cited by
131
References
2
Citations by year
2026: 10 · 2025: 20 · 2024: 26 · 2023: 18 · 2022: 20 · 2021: 26 · 2020: 10 · 2019: 1
FWCI
2.40
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Fondation Bordeaux Université (no grant number)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
chronic obstructive pulmonary disease, chemokines, chemokine receptors, COPD exacerbations, cigarette smoke, chronic inflammation, bronchial remodeling, CCL2/CCR2, CXCL12/CXCR4 axis, chemokine-targeted therapy
MeSH terms
Animals, Humans, Lung, Biomarkers, Chemokines, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review